Baylor Hamilton offers Arctic Front Cardiac CryoAblation Catheter system treatment for paroxysmal atrial fibrillation

Physicians at Baylor Jack and Jane Hamilton Heart and Vascular Hospital are the first in North Texas to offer the Arctic Front® Cardiac CryoAblation Catheter system, the first and only cryoballoon in the United States indicated to treat drug refractory recurrent symptomatic paroxysmal atrial fibrillation (PAF), a serious heart rhythm disorder that affects millions of Americans. Recently approved by the U.S. Food and Drug Administration, the cryoballoon treatment involves a minimally-invasive procedure that efficiently creates lesions around the pulmonary veins, which is the source of erratic electrical signals that cause the irregular heartbeat.

Unlike traditional ablation treatments that use radiofrequency, or heat, to destroy faulty electrical circuits in the heart, the balloon-based technology of Arctic Front is novel because it ablates cardiac tissue through the use of a coolant rather than heat, which is delivered through a catheter. This freezing technology allows the catheter to adhere to the tissue during ablation, allowing for greater catheter stability.

Dr. Kevin Wheelan, medical director of Baylor Hamilton's electrophysiology program, says, "The value of the new cryoablation technology over existing ablation methods is that it enables physicians to more safely isolate the pulmonary veins using a simple, efficient approach. This minimally invasive procedure may give patients peace-of-mind that their heart may be restored to an appropriate rhythm and they can resume their normal, daily activity following the treatment."

According to the STOP-AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) trial, which served as the basis for FDA approval, 69.9 percent of patients treated with Arctic Front achieved treatment success at 12 months, compared to 7.3 percent of patients treated with drug therapy only. The study also demonstrated that treatment with the device is safe, with limited procedure-related adverse events (3.1 percent), and a reduction in adverse events caused by atrial fibrillation when compared to drug therapy. Additionally, patients treated with Arctic Front displayed a significant reduction of symptoms, a decrease in the use of drug therapy and substantial improvements in both physical and mental quality-of-life factors. Baylor Hamilton Heart and Vascular Hospital was the lead enrolling site in the STOP-AF study in the United States and Canada.